NCT06911320View on ClinicalTrials.gov

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

PHASE1RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Healthy Volunteer StudyHepatic ImpairmentRenal Impairment
Interventions
DRUG

Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination

A single dose of BEM/RZR will be administered

Trial Locations (2)

32809

RECRUITING

Atea Study Site, Orlando

33603

RECRUITING

Atea Study Site, Tampa

Sponsors
All Listed Sponsors
lead

Atea Pharmaceuticals, Inc.

INDUSTRY